GSK Redo Doesn't Cure Generics' 'Skinny Label' Uncertainty
By Dani Kass · August 9, 2021, 10:05 PM EDT
While the Federal Circuit may have walked back part of an induced infringement ruling that left the generic-drug industry warning a fundamental law had been gutted, attorneys say the court's revised...
To view the full article, register now.